Verily
the Alphabet life-sciences subsidiary partners with Stanford and Emory universities to run a settled-solids network spanning 147 plants across 40 states and >37 million people, reporting SARS-CoV-2 N-gene RNA in ~94% of February 2026 samples (median 31,869 copies/gram).
- Country
- United States
us
stanford
network
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Wastewater-based epidemiology | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.